Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective
Institute of Biochemistry and Molecular Biology I, Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany
*
Author to whom correspondence should be addressed.
Antioxidants 2018, 7(2), 31; https://doi.org/10.3390/antiox7020031
Received: 23 January 2018 / Revised: 12 February 2018 / Accepted: 19 February 2018 / Published: 22 February 2018
(This article belongs to the Special Issue Inspired by Nature: Antioxidants and Nanotechnology)
The incidence of numerous types of cancer has been increasing over recent years, representing the second-most frequent cause of death after cardiovascular diseases. Even though, the number of effective anticancer drugs is increasing as well, a large number of patients suffer from severe side effects (e.g., cardiomyopathies) caused by these drugs. This adversely affects the patients’ well-being and quality of life. On the molecular level, tumor cells that survive treatment modalities can become chemotherapy-resistant. In addition, adverse impacts on normal (healthy, stromal) cells occur concomitantly. Strategies that minimize these negative impacts on normal cells and which at the same time target tumor cells efficiently are needed. Recent studies suggest that redox-based combinational nanotherapies may represent one option in this direction. Here, we discuss recent advances in the application of nanoparticles, alone or in combination with other drugs, as a promising anticancer tool. Such novel strategies could well minimize harmful side effects and improve patients’ health prognoses.
View Full-Text
Keywords:
tumor-stroma interaction; reactive oxygen species (ROS); chemotherapeutics; nanoparticle; cerium oxide; mitochondria; combinational therapy
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Brenneisen, P.; Reichert, A.S. Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective. Antioxidants 2018, 7, 31. https://doi.org/10.3390/antiox7020031
AMA Style
Brenneisen P, Reichert AS. Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective. Antioxidants. 2018; 7(2):31. https://doi.org/10.3390/antiox7020031
Chicago/Turabian StyleBrenneisen, Peter; Reichert, Andreas S. 2018. "Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective" Antioxidants 7, no. 2: 31. https://doi.org/10.3390/antiox7020031
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit